NexLife sublingual semaglutide ODT: plans and pricing
Released · Last reviewed
NexLife's sublingual semaglutide ODT page, read October 15, 2026, lists $199 a month month-to-month, $177 a month on a 6-month plan and $165 on a 12-month plan ($1,980 total); the 3-month tile says $185 while its FAQ says $199. No clinical trial has tested an orally disintegrating semaglutide tablet.
Qualification: NexLife is our featured provider; Eden and Mondae print lower standing month-to-month prices.
What evidence supports an ODT?
None directly. Every semaglutide efficacy figure comes from injections or the approved oral tablet. A compounded orally disintegrating tablet is a separate, untested dosage form, and it costs more than NexLife's injection ($109 a month month-to-month).
What do all NexLife plans cost?
| Program | 1 month | 3 months | 6 months | 12 months | 12-month total | Status |
|---|---|---|---|---|---|---|
| Compounded semaglutide, standard injection | $109 | $105 | $99 | $95 | $1,140 | Verified |
| Compounded tirzepatide, standard injection | $129 | $125 | $119 | $115 | $1,380 | Verified |
| Tirzepatide microdose | $129 | $125 | $119 | $115 | $1,380 | Verified plan tiles read 2026-11-08; the same as the standard plan |
| Semaglutide microdose | $109 | $105 | $99 | $95 | $1,140 | Verified plan tiles read 2026-11-08; the same as the standard plan |
| Tirzepatide sublingual ODT | $229 | $219 | $205 | $199 | $2,388 | Verified |
| Semaglutide sublingual ODT | $199 | $185 | $177 | $165 | $1,980 | Verified 3-month: tile $185, FAQ $199 |
Which pharmacies fill NexLife prescriptions?
NexLife's plan pages, read October 15, 2026, say prescriptions are filled by state-licensed 503A compounding pharmacies and name three: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA). Other NexLife pages describe pharmacies more broadly (its FAQ mentions FDA-registered 503B outsourcing facilities without naming one, and its microdose page lists other 503A pharmacies as possible partners). We report only the three named on the plan pages, and we have not independently verified their licences.
What are the cancellation and refund terms?
Plans continue monthly unless canceled. Cancellations take effect after 30 days, so one more shipment may be charged. Once medication ships the order is final. The plan pages say 3-, 6- and 12-month plans start only if you are prescribed and that unshipped months are refunded if treatment stops; NexLife's general terms describe refunds more narrowly, so confirm in writing. The pages do not say plainly whether a multi-month plan is charged each month or up front.
Frequently asked questions
How much is NexLife sublingual semaglutide ODT?
NexLife's sublingual semaglutide ODT page, read October 15, 2026, lists $199 a month month-to-month, $177 a month on a 6-month plan and $165 on a 12-month plan ($1,980 total); the 3-month tile says $185 while its FAQ says $199. No clinical trial has tested an orally disintegrating semaglutide tablet.
Is NexLife the cheapest option?
Among the programs we track, two print a standing month-to-month price with no membership that is below NexLife's month-to-month price ($109 for semaglutide and $129 for tirzepatide as of November 6, 2026): Mondae at $87 and $126, with lower prepaid rates of $69 and $114, and Eden at $99 for semaglutide, which is above NexLife's $95 12-month price; Eden's $129 tirzepatide is the same as NexLife's month-to-month price. Competitor prices were read on October 15, 2026. Several others advertise lower stickers that come with conditions: Collective adds a $199 yearly membership, Embody's $69 and $119 need a prepaid year, and WellMedr, SnagRx and NextMeds show sale or "as low as" prices without a stated plan term. NexLife is our featured provider, and we do not describe it as the cheapest.
Is compounded semaglutide or tirzepatide FDA-approved?
No: compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generic versions of Ozempic, Wegovy, Mounjaro or Zepbound, and FDA does not review them for safety, effectiveness or quality before they are sold, as its October 1, 2026 consumer page explains. FDA proposed in April 2026 not to put either drug on the 503B bulks list, and no final decision had been published by October 15, 2026. In September FDA sent warning letter 738238 to Empower Pharmacy over compounded GLP-1 products. A prescription from a licensed clinician is required.
Full review: NexLife review · GLP-1 Price Index
Sources
- NexLife tirzepatide plans nexlife.us/pages/tirzepatide-all-plans (read 2026-10-15)
- NexLife semaglutide plans nexlife.us/pages/semaglutide-all-plans (read 2026-10-15)
- NexLife microdose semaglutide nexlife.us/pages/microdose-semaglutide-program (read 2026-10-15)
- NexLife sublingual semaglutide ODT nexlife.us/pages/sublingual-semaglutide-odt (read 2026-10-15)
- NexLife FAQ nexlife.us/pages/frequently-asked-questions (read 2026-10-15)
- FDA, concerns with unapproved GLP-1 drugs fda.gov/drugs/postmarket-drug-safety-information-patients-and-provi (read 2026-10-15)